Adverse effect of Pneumocystis Jirovecii infection associated with rituximab therapy for autoimmune disease are more frequently reported in older vs. younger patient

Stone, 2010, Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis, N Engl J Med, 363, 221, 10.1056/NEJMoa0909905 2022 Bayer, 2019, Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study, Eur J Intern Med, 67, 59, 10.1016/j.ejim.2019.06.009 Al-Tawfiq, 2015, Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: a case report and literature review, J Infect Public Health, 8, 493, 10.1016/j.jiph.2014.11.006 Lopez-Olivo, 2012, Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis, JAMA, 308, 898, 10.1001/2012.jama.10857 Hainsworth, 2003, Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis, Arthritis Res Ther, 5, S12, 10.1186/ar1008 van Vollenhoven, 2015, Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years, J Rheumatol, 42, 1761, 10.3899/jrheum.150051 Deshayes, 2019, Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux, Am J Hematol, 94, 1314, 10.1002/ajh.25632 Ramos-Casals, 2003, Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly, Lupus, 12, 341, 10.1191/0961203303lu383ed Barcellini, 2018, Autoimmune hemolytic anemia, autoimmune neutropenia and aplastic anemia in the elderly, Eur J Intern Med, 58, 77, 10.1016/j.ejim.2018.05.034 Moulis, 2014, Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, 124, 3308, 10.1182/blood-2014-05-578336 Liu, 2018, Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins, Protein Cell, 9, 15, 10.1007/s13238-017-0408-4 Dostalek, 2013, Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies, Clin Pharmacokinet, 52, 83, 10.1007/s40262-012-0027-4 Rymarz, 2021, Impaired kidney function associated with increased risk of side effects in patients with small vessel vasculitis treated with rituximab as an induction therapy, J Clin Med, 10, 786, 10.3390/jcm10040786 Routledge, 2004, Adverse drug reactions in elderly patients, Br J Clin Pharmacol, 57, 121, 10.1046/j.1365-2125.2003.01875.x Jones, 2010, Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis, N Engl J Med, 363, 211, 10.1056/NEJMoa0909169 Cohen, 2006, Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks, Arthritis Rheum, 54, 2793, 10.1002/art.22025 Moore, 1995, French pharmacovigilance database system: examples of utilisation, Therapie, 50, 557 Gawai, 2020, Overview of important methods used for causality assessment of adverse drug events in pharmacovigilance, JPADR, 1, 6, 10.53411/jpadr.2020.1.2.2 Egberts, 2002, Use of measures of disproportionality in pharmacovigilance, Drug Saf, 25, 453, 10.2165/00002018-200225060-00010 Evans, 2011, 349 Woolf, 1955, On estimating the relation between blood group and disease, Ann Hum Genet, 19, 251, 10.1111/j.1469-1809.1955.tb01348.x Mielnik, 2020, Does older age have an impact on rituximab efficacy and safety? Results from the NOR-DMARD register, Drugs Aging, 37, 617, 10.1007/s40266-020-00782-x Payet, 2014, Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry, Arthritis Care Res, 66, 1289, 10.1002/acr.22314 Timlin, 2015, Rituximab for remission induction in elderly patients with ANCA-associated vasculitis, Semin Arthritis Rheum, 45, 67, 10.1016/j.semarthrit.2015.02.005 Martin-Garrido, 2013, Pneumocystis pneumonia in patients treated with rituximab, Chest, 144, 258, 10.1378/chest.12-0477 Mecoli, 2017, Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience, Clin Exp Rheumatol, 35, 671 Thery-Casari, 2020, Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis, Autoimmun Rev, 19, 102505, 10.1016/j.autrev.2020.102505 Alves, 2019, Immunosenescence: participation of T lymphocytes and myeloid-derived suppressor cells in aging-related immune response changes, Einstein (Sao Paulo), 17, 10.31744/einstein_journal/2019RB4733 Stern, 2014, Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients, Cochrane Database Syst Rev, 10.1002/14651858.CD005590.pub3 Gea-Banacloche, 2010, Rituximab-associated infections, Semin Hematol, 47, 187, 10.1053/j.seminhematol.2010.01.002 Avivi, 2019, Depletion of B cells rejuvenates the peripheral B-cell compartment but is insufficient to restore immune competence in aging, Aging Cell, 18, e12959, 10.1111/acel.12959 Barcellini, 2012, Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies, Blood, 119, 3691, 10.1182/blood-2011-06-363556 Tieu, 2020, Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines, Rheumatol Oxf Engl, 59, e24, 10.1093/rheumatology/kez640 Park, 2018, Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids, Ann Rheum Dis, 77, 644, 10.1136/annrheumdis-2017-211796 Monestime, 2021, Prevalence and predictors of patients reporting adverse drug reactions to health care providers during oral targeted cancer treatment, J Am Pharm Assoc, 61, 53, 10.1016/j.japh.2020.09.001 Holm, 2017, Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden, Pharmacoepidemiol Drug Saf, 26, 335, 10.1002/pds.4155 Faillie, 2016, Pharmacoepidemiology and its input to pharmacovigilance, Therapie, 71, 211, 10.1016/j.therap.2016.02.016 Chouchana, 2022, Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level, Clin Pharmacol Ther, 111, 605, 10.1002/cpt.2499 Waki, 2020, Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study, Medicine (Baltimore), 99, e19173, 10.1097/MD.0000000000019173